You've been automatically redirected here from Humanzyme.com, which is now part of Proteintech Group. Click here to dismiss this alert.

Role of SAS1B in Tumor Progression: Webinar Wednesdays

Role of SAS1B in Tumor Progression - Zunair Khokhar (UVA)


Zunair Khokhar, research scientist at the University of Virginia, discusses the role of SAS1B in Tumor Progression. This webinar is dedicated to the memory of Dr. John Herr.

Webinar Background: The Role of SAS1B in Tumor Progression

A key challenge in oncology drug development is finding a target that is essential for tumorigenesis yet is unique to the tumor to mitigate deleterious side-effects. This is quite rare, but Zunair discusses how SAS1B may be one of these ideal targets. This protein is involved in folliculogenesis, so it is not expressed in other cell types in the body, and data suggest that targeting this protein inhibits tumorigenesis. Listen to Zunair’s webinar to learn more about the science behind this protein.

  
Webinar Highlights
  1. SAS1B is a membrane protein involved in female egg production and its expression is restricted to multiple tumor types in adults.

  2. Targeting SAS1B with an antibody-drug conjugate kills several different cell lines.

  3. Knocking in this gene into non-cancerous cell line MCF10A5E increases migration in invasion assay and proliferation

  4. Though these data are promising, more work needs to be done to uncover the mechanism driving cancer.


Watch more Webinars

SMART DRUG DELIVERY TO FIGHT AGAINST CANCER by Samaresh Sau

A HOTAIR by  Dr Allison Porman

HOW TO OPTIMIZE IF STAINING by Dr Karolina Szczesna

CONQUERING WESTERN BLOTS by Dr William Olds


 

Webinar Wednesdays – tell the world your story

Showcase your research to the world!

- Your webinar will have a permanent residence on the Proteintech website.

- Use the Proteintech website, email newsletter and social media as your platform.

- Access to materials to record your 15-min presentation included.

Want to get involved? Click here

Events

Posted:
18 July, 2018

Share:


Back
to top